Leonteq Securities AG Invests $4.92 Million in Biogen Inc. $BIIB

Leonteq Securities AG purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 27,960 shares of the biotechnology company’s stock, valued at approximately $4,921,000.

Several other hedge funds also recently modified their holdings of BIIB. WPG Advisers LLC increased its stake in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the last quarter. Accredited Wealth Management LLC grew its stake in Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the last quarter. First Horizon Corp acquired a new position in Biogen in the 4th quarter valued at $30,000. WFA of San Diego LLC acquired a new position in Biogen in the 2nd quarter valued at $32,000. Finally, GoalVest Advisory LLC acquired a new position in Biogen in the 4th quarter valued at $35,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the topic of a number of research analyst reports. Morgan Stanley raised their target price on shares of Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research note on Thursday, April 30th. HC Wainwright reiterated a “buy” rating on shares of Biogen in a research note on Thursday, May 14th. Canaccord Genuity Group raised their target price on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. The Goldman Sachs Group raised their target price on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Finally, Tudor Pickering set a $201.00 target price on shares of Biogen in a research note on Monday, February 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $215.62.

Biogen Stock Performance

NASDAQ BIIB opened at $187.80 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The firm has a market capitalization of $27.73 billion, a price-to-earnings ratio of 20.15, a P/E/G ratio of 1.68 and a beta of 0.19. The company’s fifty day moving average is $185.39 and its two-hundred day moving average is $180.41. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts forecast that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.